Condition deep-dive · 6 min read

Restless legs syndrome — what supplements actually have evidence

Updated 2026-05-10 · Reviewed by SupplementScore editors · No sponsorships

Restless legs syndrome (RLS / Willis-Ekbom disease) is a treatable neurological condition with a clear iron-first evidence base — and a long tail of supplements that get marketed for it on much weaker evidence. Iron deficiency is the most important reversible cause: low brain iron (often present with normal hemoglobin but ferritin under 75 ng/mL) drives dopaminergic dysfunction in subcortical motor circuits. Iron repletion is the single highest-yield intervention for most patients with RLS who have low or low-normal ferritin.

Read this first. RLS deserves a clinical workup. Several common medications worsen RLS (antihistamines, dopamine antagonists, many antidepressants), and these can be modified before adding supplements. Pregnancy-related RLS, RLS in chronic kidney disease, and RLS in iron-deficiency anaemia have specific care pathways. The supplement-first approach is most appropriate after a diagnosis and after that medication review.

What actually works in trials

Tier 1 evidence · The most important intervention

Iron repletion (target serum ferritin > 75 ng/mL)

Oral ferrous bisglycinate or ferrous sulfate 65 mg elemental iron every other day; or IV iron in non-responders or in CKD-associated RLS

The 2018 IRLSSG/EURLSSG/RLS Foundation consensus recommends ferritin testing in all patients with RLS, with iron supplementation if ferritin is below 75 ng/mL or transferrin saturation below 20%. Oral iron is first-line for non-deficient or mildly low patients; intravenous iron (low molecular weight iron dextran or ferric carboxymaltose) has the better RCT evidence in RLS specifically and is appropriate for severe symptoms, malabsorption, or oral intolerance. Take oral iron on an empty stomach if tolerated; vitamin C 250 mg with the dose modestly improves absorption. Every-other-day dosing has better fractional absorption and fewer GI side effects than daily dosing.

Tier 2 evidence · Secondary intervention

Vitamin D3 (in confirmed deficiency)

2,000–4,000 IU/day to a 25-OH-D target of 30–50 ng/mL

Several observational studies and small interventional trials have associated vitamin D deficiency with RLS severity, and supplementation in deficient patients has shown symptom improvement (Wali 2015). The evidence is weaker than iron but the safety profile and the broader rationale for testing 25-OH-D in adults make this a reasonable adjunct in deficient patients.

Tier 2 evidence · Symptomatic adjunct

Magnesium (glycinate, citrate, or sustained-release)

300–500 mg elemental magnesium evenings, ≥6 weeks

Older small trials and observational data support a magnesium-sleep-RLS connection, particularly in patients with low-normal serum magnesium status or sub-RDA dietary intake. Effect is more modest than iron repletion. Avoid in advanced kidney disease.

Tier 2 evidence · Pregnancy-associated RLS

Folate (5-MTHF or folic acid)

400–1000 mcg/day; coordinate with prenatal vitamin

Folate deficiency is associated with pregnancy-onset RLS, and supplementation in deficient patients has been associated with symptom improvement. Most prenatal vitamins already include folate; the case for additional folate is patient-specific (MTHFR variants, restrictive diets).

The medication-review layer

Before adding more supplements, consider whether any of the following common contributors can be modified:

Sedating antihistamines (diphenhydramine, doxylamine — frequently in OTC sleep products) — commonly worsen RLS; switch to non-RLS-aggravating sleep aids.
Dopamine antagonists (metoclopramide, prochlorperazine, many antipsychotics) — worsen RLS by mechanism.
Antidepressants — most SSRIs/SNRIs and TCAs aggravate RLS; bupropion is a notable exception that's often better tolerated.
Caffeine, nicotine, alcohol — modifiable lifestyle inputs that commonly aggravate RLS.

The sleep-supportive layer

RLS dramatically disrupts sleep onset and maintenance. Sleep-supportive supplements that don't worsen RLS:

Magnesium glycinate 300–400 mg evenings — covered above.
L-Theanine 200 mg at bedtime — can help sleep onset without antihistamine activity.
Glycine 3 g at bedtime — modest sleep maintenance benefit.
Melatonin 0.3–0.5 mg 30–60 minutes pre-bedtime — small dose for circadian timing rather than sedation; higher doses don't help RLS specifically.

What to skip

Generic "leg cramp" formulas with quinine — quinine has been pulled by FDA for this indication due to serious adverse-event signals (thrombocytopenia, cardiac arrhythmias).
"RLS gummies" with herbal blends — these typically contain sub-therapeutic doses of magnesium plus poorly characterised herbal extracts; not a substitute for ferritin-driven iron repletion.
5-HTP standalone — limited RLS-specific evidence and serotonin syndrome risk in patients on SSRIs/SNRIs makes it a poor fit.
"Adrenal support" formulas — irrelevant to RLS pathophysiology.
Megadose iron without testing — iron overload (haemochromatosis, transfusion-related) is common enough that empirical iron loading without ferritin is inappropriate.

What to track

The International Restless Legs Scale (IRLS) is a 10-item validated scale; weekly tracking gives a reasonable signal. Pair it with a sleep diary or a validated sleep-quality scale (PSQI). Reassess ferritin at 12 weeks of oral iron repletion; the target is >75 ng/mL with TSAT >20%. If oral iron has not raised ferritin meaningfully despite adherence, malabsorption (coeliac disease, atrophic gastritis, prior bariatric surgery) deserves workup, and IV iron becomes the better option.

Practical quick-start. Test ferritin, transferrin saturation, 25-OH-D, and B12. Review medication list for RLS-aggravating agents with the prescriber. Then: oral iron (ferrous bisglycinate 65 mg elemental every other day) if ferritin under 75 ng/mL, plus magnesium glycinate 300 mg evenings. Reassess at 12 weeks. If pharmacological RLS treatment is needed, those decisions belong with sleep medicine or neurology — supplements are an adjunct.